These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 36028979

  • 1. Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
    Garcia-Horton A, Cyriac SL, Gedde-Dahl T, Floisand Y, Remberger M, Mattsson J, Michelis FV.
    Eur J Haematol; 2022 Dec; 109(6):672-679. PubMed ID: 36028979
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY, Ren HY, Qiu ZX, Wang Y, Cen XN, Wang LH, Wang MJ, Xu WL, Wang WS, Li Y, Dong YJ, Ou JP, Liang ZY, Liu W, Wang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E, Demiroğlu H, Büyükaşık Y, Göker H.
    Turk J Haematol; 2021 Jun 01; 38(2):138-144. PubMed ID: 32539316
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2010 Mar 01; 16(3):413-20. PubMed ID: 19922807
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB.
    Transplant Cell Ther; 2023 Jun 01; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [Abstract] [Full Text] [Related]

  • 7. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL, López-Anglada L, Rovira M, Bosch F, Carreras E, Corral LL, Sierra J, Valcárcel D.
    Biol Blood Marrow Transplant; 2014 Jan 01; 20(1):66-72. PubMed ID: 24141006
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y, Zhang JP, Zhao YL, Xiong M, Sun RJ, Cao XY, Wei ZJ, Zhou JR, Liu DY, Yang JF, Zhang X, Lu DP, Lu P.
    Front Immunol; 2022 Jan 01; 13():1066748. PubMed ID: 36685540
    [Abstract] [Full Text] [Related]

  • 9. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.
    Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA.
    Biol Blood Marrow Transplant; 2017 Jan 01; 23(1):67-74. PubMed ID: 27789361
    [Abstract] [Full Text] [Related]

  • 10. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.
    Jullien M, Orvain C, Berceanu A, Couturier MA, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, Hunault M, Daguindau E, Roussel X, Delepine P, Guillerm G, Giltat A, François S, Thepot S, Le Gouill S, Béné MC, Chevallier P.
    Cancer Med; 2021 Oct 01; 10(20):7194-7202. PubMed ID: 34547182
    [Abstract] [Full Text] [Related]

  • 11. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
    Fernández-Caballero M, Jiménez Lorenzo MJ, Morgades de la Fe M, Ferrà Coll C, Vives Polo S, Abril Sabater L, Navarro Ferrando JT, Ribera Santasusana JM.
    Med Clin (Barc); 2022 May 27; 158(10):451-457. PubMed ID: 34404519
    [Abstract] [Full Text] [Related]

  • 12. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P.
    Leukemia; 2009 Jun 27; 23(6):1131-8. PubMed ID: 19194465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF.
    Biol Blood Marrow Transplant; 2016 Mar 27; 22(3):584-8. PubMed ID: 26631751
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.
    Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, Rashad AH, Woolfrey AE, Appelbaum FR, Storb R, Sorror ML.
    Biol Blood Marrow Transplant; 2019 May 27; 25(5):1045-1052. PubMed ID: 30500442
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC.
    Cancer; 2018 Apr 15; 124(8):1733-1742. PubMed ID: 29424927
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.
    Biol Blood Marrow Transplant; 2014 Mar 15; 20(3):402-408.e1. PubMed ID: 24342394
    [Abstract] [Full Text] [Related]

  • 18. The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes.
    Singh S, Cao Q, Demorest C, He F, Kramer A, Holtan S, Juckett M, Ramesh V, Arora M, Maakaron J, Weisdorf D, El Jurdi N.
    Transplant Cell Ther; 2024 Sep 15; 30(9):919.e1-919.e9. PubMed ID: 38838780
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
    Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA, Kumar A, Murthy HS.
    Clin Lymphoma Myeloma Leuk; 2020 Oct 15; 20(10):e694-e711. PubMed ID: 32616401
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
    Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH.
    Biol Blood Marrow Transplant; 2019 May 15; 25(5):1039-1044. PubMed ID: 30639822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.